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List of Abbreviations
 
AF = Atrial Fibrillation
BMI = Body Mass Index
BP = Blood Pressure
CV = Cardiovascular
DM = Diabetes Mellitus
eGFR = estimated Glomerular Filtration Rate
FS = Fractional Shortening
HDL = High Density Lipoproteins
IFG = Impaired Fasting Glucose
IVRT = Isovolumic Relaxation Time
LDL = Low Density Lipoprotein
LIFE = Losartan Intervention For Endpoint reduction in hypertension
LVH = Left Ventricular Hypertrophy
LVM = Left Ventricular Mass
MAC = Mitral Annulus fibro-Calcification 
MetS = Metabolic Syndrome
NFG = Normal Fasting Glucose
PP = Pulse Pressure
RAS = Renin-Angiotensin System
RWT = Relative Wall Thickness
SV = Stroke Volume
S           = Study
UACR = Urinary Albumin-Creatinine Ratio
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Scientific Environment
The present project was undertaken in the Department of Translational Medical Sciences at 
the Federico II University of Naples in Italy. The Research Group is chaired by Professor 
Giovanni  de  Simone  and  currently  includes  2  Full  Professor,  2  Associate  Professors,  2 
Assistant  Professor and 2 Ph.D. students.  Several  research medical  students  and resident 
fellows cooperate in the research activities. 
The Research Group has specialized in cardiovascular epidemiology, with a focus on 
cardiovascular prevention, through understanding cardiovascular modifications related to the 
main risk factors, such as diabetes, obesity, and hypertension. The research group facilities 
includes  advanced  echocardiographic  laboratories  with  dedicated  workstations  for  post-
processing of images and data analyses and outpatients clinics for management of research 
patients. During my Ph.D., I was introduced to this new world of research by Dr. Marcello 
Chinali,  at  the  time  when  he  was  a  postdoctoral  fellow  and  supervisor  in  the 
echocardiography  laboratory.  I  had  also  the  opportunity  to  work  closely  with  Professor 
Giovanni de Simone together with Professors Bruno Trimarco, Nicola De Luca and Raffaele 
Izzo on several research projects involving exploration of the large database of hypertensive 
patients referred to the Hypertension Center of the Federico II University of Naples (the 
Campania Salute Network).
The  Research  Group  is  part  of  a  large  international  network,  embracing  several 
research centres in different countries. This worldwide research network has given me the 
opportunity  to  perform  research  on  large  databases  based  upon  international  research 
projects, including the Strong Heart Study, the Losartan Intervention For Endpoint reduction 
in  hypertension  (LIFE)  Study  and  the   Hypertension  Genetic  Epidemiology  Network 
(HyperGEN) Study. The main international partners are the Department of Cardiology at the 
Weill-Cornell Medical College in New York, USA (by Professor Richard B. Devereux) and 
the  Department  of  Clinical  Science at  the  University  of  Bergen in  Bergen,  Norway (by 
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Professor Eva Gerdts). During the course of my Ph.D. I had the opportunity to visit and 
collaborate with both of them: in New York working with Professor Devereux on the impact 
of diabetes in adolescents and young adults, and in Bergen working with Professor Gerdts on 
new echocardiographic risk markers in hypertension. I also had the chance to work closely 
with Professor Gerdts for one year, during her visit as Guest Professor in Naples in 2011. 
During this year, I had the opportunity to collaborate with other postdoctoral fellows of the 
Bergen Hypertension and Cardiac Dynamics group in Bergen, especially with postdoctoral 
fellow PhD. Mai Tone Lønnebakken who is actually going to spend one year as visiting 
guest researcher in the Hypertension Research Center in Naples.
I have had an active rule in development of the studies presented in my thesis, by 
ideating, proposing and submitting these research projects, analyzing data and performing 
statistical analyses, elaborating and interpreting results and writing manuscripts.
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Summary
Background: Cardiovascular  (CV)  risk  factors  like  obesity,  hypertension  and  type  2 
diabetes have increased dramatically over the last decades, also in younger age classes. In 
hypertension,  clustering  of  metabolic  risk  factors  have  been  associated  with  resistant 
hypertension, but is not known whether this may be overcome by specific pharmacological 
treatments. Moreover, whether specific metabolic risk factors, like diabetes, are associated 
with  preclinical  CV  disease  also  in  young  age  is  not  well  explored.  Finally,  whether 
identification  of  new markers  of  CV disease  by  echocardiography,  related  to  these  risk 
factors, might help to further refine the high risk CV phenotype is unknown, though this 
evidence would be critical to improve risk stratification in the individual beyond current state 
of the art. 
Aims: The main aim of the Ph.D. project has been to evaluate the impact of metabolic risk 
factors  on blood pressure  control  and CV phenotype,  identifying new echocardiographic 
predictors of CV disease in different populations. Specific sub-goals were:
Study  1 (S1)  –  To evaluate  the  impact  of  clustering  of  metabolic  risk  factors  on blood 
pressure control in relation to different classes of medications;
Study 2 (S2) – To assess the impact of metabolic risk factors, as diabetes and pre-diabetes on 
preclinical CV disease in adolescents and young adults;
Study  3  (S3)  –  To  identify  new  echocardiographic  markers  of  CV  events  in  treated 
hypertensive patients with high risk CV profile. 
Methods: For  the  specific  scope  of  the  studies  we  analyzed  different  populations. 
Specifically,  in  S1 we  evaluated  the  impact  of  metabolic  syndrome  on  the  risk  of 
uncontrolled  blood  pressure  (i.e.  blood  pressure≥140/90  mmHg  under  antihypertensive 
treatment), in relation to specific antihypertensive medications. The analysis was carried out 
at baseline and after a mean follow-up of 5 years in 4,612 (53±11 years, 43% women; 25% 
with obesity, 9% with diabetes) hypertensive patients without prevalent CV disease, referred 
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to our tertiary Hypertension Center from the Campania Salute Network. In S2 we evaluated 
the  impact  of  diabetes  and  pre-diabetes  on  cardiac  structure  and  function  in  1,624 
adolescents  and  young  adults  American-Indians  (179  with  diabetes  and  299  with  pre-
diabetes). These were participants of the Strong Heart Family Study (mean age 27±8 years, 
57% female, 66% with obesity, 19% with hypertension) free of prevalent CV disease.
Finally, in S3 we evaluated the prognostic impact of presence of mitral annulus calcification 
(MAC) on incidence of ischemic stroke. For this sub-goal we analyzed baseline and 5 years 
follow-up  data  from  939  treated  hypertensive  patients  (458  with  MAC)  with 
electrocardiographic signs of left ventricular hypertrophy (LVH) (66±7 years, 42% women, 
23%  with  obesity,  11%  with  diabetes)  participating  in  the  Losartan  Intervention  For 
Endpoint reduction in hypertension (LIFE) echocardiography sub-study.
Results: In S1 we found that despite the increased use of medications, hypertensive patients 
with metabolic syndrome had higher risk of uncontrolled blood pressure, independently of 
specific therapy. Among classes of medications, increased prescriptions of diuretics, renin-
angiotensin  system antagonists  and  also  statins  decreased  the  probability  of  poor  blood 
pressure control.
In S2 we found that diabetes was independently associated with early and unfavorable 
CV phenotype characterized by increased left  ventricular  mass,  concentric  geometry and 
preclinical  systolic  and  diastolic  dysfunction.  Early  CV alterations  were  also  present  in 
participants with pre-diabetes. 
In  S3 we  found  that  risk  of  incident  ischemic  stroke  was  significantly  related  to 
presence of MAC, independently of traditional CV risk factors, as increased left ventricular 
mass and left atrial diameter, prevalence or incidence of atrial fibrillation and albuminuria. 
Conclusions: These results document that: 1) in hypertension, clustering of metabolic risk 
factors  strongly  interferes  with  efficacy  of  therapy,  2)  in  addition  to  obesity  and 
hypertension, diabetes and pre-diabetes have an important impact on cardiac structure and 
function, even in young age, 3) MAC identifies increased risk of  stroke in hypertensive 
patients with LVH. 
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Introduction
Introduction
Cardiovascular  (CV) disease  is  the  major  cause  of  death and disability  in  Western 
countries  [1,2],  and  contributes  substantially  to  the  escalating  health  care  costs.  The 
reduction of CV disease burden depends on the ability of physicians and health care systems 
to  implement  the  control  of  CV risk  factors  through  effective  program of  primary  and 
secondary prevention  [3]. Lack of control  of common CV risk factors like hypertension, 
obesity and diabetes is together with the aging of Western population the main causes of 
continuous increase in incidence and prevalence of CV disease [4].
Obesity  is  increasing in  epidemic  proportions  in  industrialized  and  developing 
countries, affecting both adults [5] and children and adolescents [6,7]. Obesity predisposes to 
arterial hypertension and diabetes and there is extensive evidence that these risk factors tend 
to cluster together amplifying the unfavourable effect of each single risk factor on incidence 
of disease [8-16], also reducing the efficacy of the treatment [17-22]. 
In  this  regard,  there  is  evidence  that  management  of  hypertension  is  particularly 
difficult when this condition co-exists with obesity and/or clustering of metabolic risk factors 
[22-25].  Hypertension indeed is often part of a constellation of CV risk factors including 
obesity,  abnormal  glucose  homeostasis  and  dyslipidemia,  supporting  the  existence  of  a 
discrete  disorder,  often  referred  to  as  the  metabolic  syndrome  (MetS)  [26-28].  MetS 
increases CV risk in the setting of hypertension, even when taking individual risk factors into 
account  [12-14],  and  reduces  the  probability  of  achieving  optimal  blood  pressure  (BP) 
control, despite more aggressive treatment [22-25]. 
This  is  a  very  important  health  problem,  since  arterial  hypertension  is  the  most 
prevalent CV risk factor in most populations, and the leading cause for medical consultation 
and drug prescriptions [29]. It has been estimated that 26% and 28% of incident CV disease 
in  men  and  women,  respectively,  are  primarily  attributable  to  hypertension  [8].  The 
continuous large impact of hypertension on incident CV disease may be related to the fact 
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that BP in hypertensive patients is still  largely uncontrolled, despite the large number of 
prescribed medications [30,31]. The risk of uncontrolled BP increases with the number of 
metabolic  risk  factors  [22],  but  whether  the  use  of  different  types  of  antihypertensive 
medications influence this association has not been clarified yet. 
Figure 1 shows the complex interaction between the CV risk factors, preclinical CV 
disease with asymptomatic modifications on cardiac and arterial structure and function which 
precedes clinical CV disease and events. Thus, in addition to the interference on the efficacy 
of therapy, there is also growing evidence that obesity related CV risk factors, alone or in 
combination, may have particular adverse impact on development of preclinical CV disease 
[32-41]. 
Figure 1 – From risk factors to overt CV diseases through preclinical stage
-
Accordingly, early detection and management of these risk factors and the associated 
preclinical  target organ damage represents the major health strategies in order to prevent 
incident  CV  disease  and  optimize  preventive  and  therapeutic  strategies.  This  is  very 
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important, especially in adolescents and young adults, since the rising prevalence of obesity 
and associated risk factors among the younger ages is now a major health concern with both 
epidemiological and economic implications [6,7,42-45].  Early identification of preclinical 
disease  in  adolescents  and  young  adults  is  also  of  great  interest  to  understand 
pathophysiological mechanisms related to a specific risk factor, since in general the time of 
exposure  is  usually  lower  compared  to  adults  and  also  the  interference  due  to  other 
confounding  prevalent  diseases  is  lower.  Moreover,  cardiometabolic risk factors  tend  to 
remain stables from childhood to adulthood and are predictive of future CV disease [46-49]. 
Thus,  increasing  efforts  are  needed  to  identify  young  individuals  at  high  CV  risk  by 
detection early markers of disease to optimize early intensive interventions to prevent or 
delay future disease [50]. 
In particular, type 2 diabetes (DM) in young subjects has increased dramatically in the 
last decade [51],  especially in minority populations,  like the American Indians [52].  The 
decline in the age of onset of type 2 DM is driven by the increasing obesity in the younger 
age  group  [53,54].  Early  onset  of  type  2  DM  is  associated  with  increased  risk  of  CV 
complications compared to usual onset of the disease [55-61]. Comparison of cardiovascular 
risk profiles between early (<40 years of age) and later-onset (>40 years of age), showed that 
a  significantly  greater  clustering  of  multiple  CV  risk  factors  (obesity,  hypertension, 
dyslipidaemia) is more common among early-onset type 2 DM subjects [60,61]. 
However, part of the increased CV risk may be related to a direct adverse effect of DM 
on the heart, independently of coronary artery disease, as it has been documented in elderly 
adults [18, 62-64]. Previous population based studies have shown an early adverse impact of 
obesity  and  associated  risk  factors  including  hypertension  on  cardiovascular  system  in 
adolescents and young adults [43-45], but  the impact of DM and pre-diabetes on cardiac 
geometry and function in adolescents and young adults has never been targeted in a large 
population-based samples. Thus, it was unknown whether there might be also an independent 
influence of DM on CV phenotype at young age. 
As shown in Figure 1, the overall CV risk attributable to the metabolic risk factors may 
not only be determined by their presence, but mediated by their impact on CV phenotype. In 
hypertension, accurate and sensitive assessment of CV risk allows better stratification of the 
individual risk, and is a key step toward optimizing the management of hypertensive patients 
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[65]. It has also been proved that identifying and targeting the subset of patients who are at 
highest risk improves the cost-effectiveness of antihypertensive treatment, for any degree of 
BP reduction [66].  
Identification  of  new  ultrasound  markers  of  preclinical  CV disease,  might  help  to 
further refine identification of high-risk CV phenotype and improve preventive strategies, 
also  in  hypertensive  individuals  with  high  CV  risk  based  on  traditional  criteria  [65]. 
Echocardiographic detection of calcification of the cardiac valves has been associated with 
increased CV risk [67-73]. In particular, fibro-calcification of the mitral annulus (MAC) is 
often found on the echocardiogram, appearing as a bright echo dense region at the level of 
the  mitral  annulus.  MAC  is  an  age-related  degenerative  process  [74],  involving  lipid 
deposition, fibrosis and calcification of the mitral valve support ring [75]. In hypertension, 
MAC  has  been  considered  an  incidental  finding,  even  if  it  is  strongly  associated  with 
metabolic  risk  factors  for  development  of  atherosclerosis  [76-80].  Thus,  MAC  may  be 
proposed as an easily measurable barometer of the burden of atherosclerotic disease [79] and 
its presence may reflect the intensity and duration of exposure to these risk factors over time 
[77,80].  Whether  arterial  hypertension  in  itself  accelerates  the  development  and/or 
progression of MAC through increased mitral valve stress and hypertension associated risk 
for thrombosis and atherosclerosis is not known. In particular, the independent association of 
MAC with subsequent risk for incident stroke has never been previously evaluated in treated 
high-risk hypertensive patients. Previous  population based studies in Framingham and in 
Northern  Manhattan  in  New  York,  have  suggested  that  the  presence  of  MAC  is 
independently  associated  with  a  higher  incidence  of  CV disease  and CV death  [69,70]. 
However,  to  date,  its  detection does  not  modify  treatment  recommendations  or  alter  the 
intensity of therapies for associated conditions [81] because no extenive data are available on 
its possible independent CV risk.  Specifically, several [71-73] but not all [82], population-
based studies, have reported a significant association between MAC and risk of ischemic 
stroke. However the existence of incremental independent predictive value of MAC above 
other established risk factors for ischemic stroke has been questioned [73,82]. In particular, 
the independent association of MAC with subsequent risk for incident stroke has never been 
previously  evaluated in treated high-risk hypertensive patients.
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Objectives
The overall objective of this Ph.D. thesis was to assess the impact of metabolic risk factors 
on the efficacy of antihypertensive therapy and on prevalence and incidence of preclinical 
and clinical CV disease, evaluating new predictors of clinical disease (Figure 2).
Figure 2– Main scope of  the Ph.D. program: from metabolic risk factors to disease through 
impact of therapy and preclinical target organ damage
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Accordingly, the specific sub-goals of the three studies (S) were:
S1.  To evaluate the impact of clusters of metabolic risk factors in relation to efficacy of 
different classes of medication, on BP control in a large population of hypertensive 
patients;
S2.  To evaluate the independent impact of diabetes and pre-diabetes on cardiovascular 
phenotype in a large population of adolescent and young adults without clinical CV 
disease;
S3.  To evaluate the  independent  prognostic  impact of fibro-calcification of  the mitral 
annulus  on  incidence  of  ischemic  stroke  in  a  large  cohort  of  high-risk  treated 
hypertensive patients.




For  the  specific  scopes  of  the  three  sub-goals  we  utilized  existing  databases  from 
different populations. 
Sub-goal 1 (S1) was implemented by utilizing data from the register of the Campania 
Salute Network, including a large population of outpatients clinical hypertensive patients, 
providing  a  rare  opportunity  to  validate  therapeutics  strategies  in  an  unbiased  real-life 
context. As previously reported [22, 83-85], this is an open electronic registry generated from 
a network of 23 community hospital-based hypertension clinics and 60 general practitioners, 
referring to the Hypertension Center of the Federico II University Hospital (Naples, Italy), in 
the  Campania  District  (Campania  Salute  Network,  web  site: 
http://www.campaniasalute.com/).  The  registry  includes  over  12,000  patients,  who  were 
given a smart-card including demographics and clinical information. After the fist enrolment 
visit, all participants were followed-up at the Outpatient Clinic of our Hypertension Center. 
The data-base generation of the Campania Salute Network was approved by the Federico II 
University Hospital Ethic Committee. Signed informed consent for using data for scientific 
purposes  was  obtained  from all  participants.  During  initial  and  follow-up visits,  clinical 
examinations,  including  a  personal  interview and measurement  of  BP,  body  mass  index 
(BMI),  fasting  glucose,  and  lipid  profile  by  were  performed  standard  methods  in  each 
patients.  Systolic  and  diastolic  BP  was  measured  by  regularly  calibrated  aneroid 
sphygmomanometer after 5 minutes resting in the sitting position, in accordance with current 
guidelines [29,65]. Three BP measurements were obtained during each office visit, at 2 min 
intervals and the averages of the allmeasurements  were used for analysis. For the goal of the 
S1, we selected 7,752 hypertensive patients without clinical CV disease (previous myocardial 
infarction  or  angina  or  procedures  of  coronary  revascularization,  stroke  or  transitory 
ischemic attack, congestive heart failure) or diagnosis of secondary hypertension. From the 
initial  event-free  hypertensive  population,  2,911  patients  were  excluded  because  of 
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insufficient follow-up period (i.e. last available visit performed less then 1 year from the 
initial  visit),  27 because  of  chronic  kidney disease  of  more  than stage 3 (by glomerular 
filtration rate estimated by Modification of Diet in Renal Disease formula [eGFR]) [86] and 
202  because  of  missing  information  on  BP or  metabolic  status.  Thus,  the  S1 analysis 
included  4,612  hypertensive  participants,  free  of  prevalent  CV disease. BP control  was 
assessed at  the last available visit in all patients, on average after 5.0±3.4 years of follow up. 
The number and type of antihypertensive medication prescribed at the time of the first and 
last available visit was used for the analysis. Antihypertensive medication was classified as: 
diuretics,  β-blockers  (including  β-blockers  and  α-β  blockers),  Renin-Angiotensin  System 
blockers  (including  ACE-inhibitors  and  angiotensin  receptor  blockers,  [RAS-blockers]), 
calcium-channel blockers and α-blockers. 
For sub-goal 2 (S2), we used an established database from a large population based-
sample  of  adolescents  and young adults,  free  of  clinical  CV disease  participating in  the 
Strong Heart  Family  Study.  The  Strong  Heart  Study  is  a  longitudinal  population-based 
survey of CV risk factors and disease in American Indian from 13 communities in Arizona, 
Oklahoma and South and North Dakota [87-90]. The fourth phase examination, conducted 
between 2001 and 2003, enrolled members of large three-generation families (Strong Heart 
Family  Study)  [43-45]  including  1,944  under  40  years.  During  this  examination,  all 
participants underwent transthoracic Doppler echocardiography. As previously reported [43-
45,87-90],  clinical  examinations,  including  a  personal  interview,  physical  examination, 
bioelectric impedance examination  and morning blood sample collection after a 12-hour 
fast, were performed at local community settings and Indian Health Service clinics by the 
study staff.  Brachial  BP was measured  3 consecutive  times on  seated  participants  using 
appropriately sized cuffs. The mean of the last 2 measurements was used. Participants (or 
their parent or guardian in the case of minors) gave written informed consent under protocols 
approved by all participating communities and institutional review boards. For the purpose 
of the  S2, 33 participants were excluded because prevalent CV disease: 2 with history of 
heart failure, 11 with prevalent coronary artery disease, 6 with previous stroke, 1 because of 
previous valve replacement,  and 13 with echocardiographic evidence of significant valve 
disease  (aortic  or  mitral  stenosis  or  regurgitation  more  than  mild).  In  addition,  287 
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participants  were  also  excluded  because  of  missing  information   on  diabetes  status. 
Accordingly, in  S2 we analyzed data from 1,624 adolescents and young adults participants 
(57% female; age range 14-to-39, mean age 26.6±7.7 years), free of prevalent CV disease. 
Sub-goal  3 (S3)  was  tested  using  data  from  treated  hypertensive  patient   with 
electrocardiographic signs of left ventricular (LV) hypertrophy (LVH) from the  Losartan 
Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy. 
As previously reported [91-94], the LIFE trial enrolled 9,193 hypertensive patients aged 55-
80 years with baseline mean seated BP in the range of 160 to 200 mmHg systolic and/or 95 
to 115 mmHg diastolic after 1 to 2 weeks of placebo treatment, and electrocardiographic 
signs  (by  either  the  sex-adjusted  Cornell  voltage  duration  or  the  Sokolow-Lyon  voltage 
criteria)  of  LVH.  At  enrolment,  history  of  previous  CV disease,  atrial  fibrillation  (AF), 
diabetes and smoking habits were reported by patients and investigators. At baseline and at 
each  annual  visit,  clinical  measurements  including  sitting  BP,  electrocardiography  and 
laboratory analyses were recorded. The LIFE echocardiography sub-study was prospectively 
planned to enrol 10% of the parent trial population for additional annual echocardiographic 
evaluation during the 5-year follow-up [17,18,94]. The conduct of the LIFE study complied 
with the Declaration of Helsinki. All patients gave written informed consent under protocols 
approved by institutional  review boards at  each participating institution.  The S3 analysis 
excluded  participants  in  the  LIFE  echocardiography  sub-study  with  missing  baseline  or 
follow-up data on MAC (N=3), or that had evidence of baseline aortic (N=15) or mitral valve 
stenosis  (N=1)  or  valve  prosthesis  (N=2).  Thus,  in  S3 we  analyzed  clinical  and 
echocardiographic  data  in  939 treated hypertensive  patients  (mean age 66±7 years,  42% 
women).  In-treatment BP,  metabolic profile  and CV phenotype were assessed by annual 
study  visits,  laboratory  analyses  and  echocardiograms  until  the  end  of  the  trial  or  the 
occurrence  of  a  CV event  in  patients  who experienced a  primary  study endpoint  (mean 
follow-up 4.8±0.9 years). 
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Clinical and Metabolic Classification and Definitions
Arterial hypertension was defined as systolic BP ≥140 mmHg and/or diastolic BP ≥90 
mmHg or current use of antihypertensive therapy [29,65]. Moreover, systolic and/or diastolic 
BP above  95th percentile  of  the  normal  distribution  for  age,  gender  and  height  defined 
hypertension in  participants  younger  than 18 years  of  age  [95].  During  antihypertensive 
treatment, BP was considered uncontrolled if systolic BP≥140 mmHg and/or diastolic BP 
≥90 mmHg was present [29,65,96].  Pulse pressure  (PP) was calculated as the difference 
between systolic and diastolic BP.
BMI  was  calculated  from  body  weight  divided  by  height  in  meters2. BMI-for-age 
charts, developed by the National Center for Health Statistics, were used in participants <18 
years  old.  Obesity was defined by the  95th percentile  of  the normal  distribution  [43,97]. 
Guidelines correction was applied [43,98,99] so that all participants with BMI ≥30 kg/m2 
were  considered  obese.  In  the  Strong  Heart  Study,  percent  body  fat  was  estimated  by 
bioelectric impedance analysis (model B14101, RJL Equipment Co, Detroit, MI) and waist 
circumference and waist/hip ratio were used as indicators of central adiposity [98]. Insulin 
resistance was estimated from fasting plasma insulin and glucose using the Homeostasis 
Model Assessment (HOMA) index (100-103), a method validated by comparison with the 
hyperinsulinemic euglycemic clamp technique (104). DM was defined from fasting glucose 
≥126 mg/dl or from use of insulin or oral hypoglycemic therapy. Pre-diabetes was defined by 
IFG, from fasting glucose between 100 and 125 mg/dl [105]. In DM, good diabetic control 
was defined as HbA1c <7% [105]. In the LIFE study, DM was defined by the World Health 
Organization  criteria  for  fasting  or  random  serum  glucose  or  use  of  hypoglycaemic 
medications [18,19,106,107]. In the patients from the Campania Salute Network, a modified 
ATP III definition of MetS [108] was used, replacing waist girth with BMI ≥30 kg/m2, the 
cut-point for definition of obesity, according to the National Institutes of Health guidelines 
[98], consistent with a number of previous studies [12,14,21,22]. Diagnosis of MetS required 
at  least  two of the  following metabolic risk factors,  being the  third factor  present  in all 
participants (hypertension): fasting plasma glucose ≥110 mg/dl, plasma triglycerides ≥150 
mg/dl,  high density  lipoprotein (HDL) cholesterol  <40 mg/dl for  men,  or <50 mg/dl for 
women, and BMI ≥30 kg/m2.
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In  the  LIFE  study,  baseline  and  annual  in-study  follow-up  electrocardiograms 
underwent  Minnesota  coding  for  atrial  fibrillation  (AF)  at  the  ECG  core  center  [109]. 
Presence of AF was defined by reported history of AF or by its identification at baseline or 
follow-up electrocardiograms. During the baseline and follow-up visits, morning blood and 
spot-urine  sample  were  also  collected.  Measurements  of  serum and urine  analyses  were 
performed at 2 central laboratories by standard methods [110,111]. eGFR was calculated by 
the  simplified  Modification  of  Diet  in  Renal  Disease  equation  [86].  Urinary  albumin 
excretion was measured on a single spot urine sample and was expressed in relation to grams 
of urinary creatinine (UACR) [112,113]. Albuminuria was defined as UACR ≥ 30 mg/g [86, 
105].
In the LIFE study, incident CV events were adjudicated by an independent end-point 
committee blinded to the treatment study allocation [91].  Stroke was defined as a new-onset 
neurological  deficit  of  vascular  origin  lasting  24  hours  or  longer  or  until  death.  Stroke 
classification was based on categories developed in the Framingham Study [114]. Ischemic 
stroke  was  assigned  in  the  absence  of  evidence  of  primary  intracranial  bleeding,  while 
hemorrhagic stroke required evidence of haemorrhage (i.e. bloody spinal fluid or blood on 
computed tomography), excluding cases of vessel rupture due to traumatic, neoplastic, or 
infectious processes.  Clinical  centers  provided information on neurologic  deficits  on end 
point narrative forms [115]. 
Echocardiographic Measures
As previously reported, in the Strong Heart Study [43,44,62], and in the LIFE study 
[17,18,94],  echocardiograms  were  performed  in  all  participants  by  expert  sonographers, 
following  a  standardized  imaging  protocol,  and  images  were  reviewed  off-line  by  2 
independent readers in the Cornell Echocardiography Core Reading Center, following the 
American Society of Echocardiography recommendations [116,117].  
LV  mass  (LVM)  was  calculated  by  a  necropsy-validated  formula  [118]  and  was 
normalized  to  height  in  meters2.7 (LVM index)  [119].  LVH was  defined  using  previous 
reported  age  and  sex-specific  partition  values  (LVM  index  >38.5g/m2.7 for  female  and 
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>40.7g/m2.7 for male participants up to 20 years old; LVM index>46.7g/m2.7 for women and 
>49.2g/m2.7 for men over 20 years, respectively) [43,119]. 
Relative  wall thickness (RWT) was calculated as myocardial thickness (end-diastolic 
posterior wall plus septum or alternatively as 2 times end-diastolic posterior wall thickness) 
divided  by  LV  internal  dimension  [120] and  normalized  for  age  [121].  Concentric  LV 
geometry was defined as age-adjusted RWT>0.40 [121]. 
Stroke volume (SV) was computed as the difference between end-diastolic and end-
systolic volumes by the z-derived method [122] and was normalized to height in meters2.04 
[123]. Ejection fraction was obtained by the ratio of SV to end-diastolic volume. The ratio 
between pulse pressure and SV (PP/SV) was used as a raw indicator of total arterial stiffness.
Stroke work, a measure of cardiac workload, was calculated multiplying systolic BP 
(pressure load) × SV (volume load) × 0.014 [124]. To establish whether increased LVM was 
compensatory  for  increased  cardiac  workload  or  instead  was  inappropriately  high,  we 
calculated the individual theoretical ideal value of LVM (predicted LVM), using age specific 
equations generated by stroke work, gender and height2.7 [43,124,125]. The value of LVM 
directly measured from echocardiograms was divided by the value of predicted LVM by the 
individual hemodynamic load and expressed in % of predicted value. Inappropriately high 
LVM was considered present if the ratio of measured/predicted LVM was >109% up to age 
20, and >128% above age 20 years [43,124]. To generate estimates of LV systolic function 
independent of myocardial afterload, we calculated LV minor axis fractional shortening (FS) 
at  either  endocardial  or  midwall  levels,  in  relation  to  circumferential  end-systolic  stress 
(stress-corrected  endocardial  FS  and  stress-corrected  midwall  FS)  using  a  previously 
validated formula [126,127]. Stress-corrected midwall FS is a measure of wall mechanics 
that  reflects  myocardial  contractility  independently  of  LV  geometry,  whereas  ejection 
fraction and stress-corrected endocardial FS are more influenced by LV geometry [128].
LV  diastolic  function  was  assessed  by  Doppler  interrogation  of  transmitral  blood 
velocity  at  early  (E)  and  late  (A)  LV filling,  their  ratio,  the  deceleration  time  of  early 
diastolic LV filling and the atrial filling fraction. Isovolumic relaxation time (IVRT), a raw 
index of active LV relaxation, was measured between aortic valve closure and mitral valve 
opening. Doppler measurements were obtained offline from an average of several cardiac 
cycles. Heart rate was measured simultaneously [45,129].  
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Presence of MAC was identified qualitatively as the presence of bright echoes at the 
base  of  the  posterior  mitral  leaflet  on  M-mode  or  2D  imaging  in  parasternal  or  apical 
windows at the baseline echocardiogram or at the last available echocardiogram before the 
ischemic stroke event. 
Statistical Analysis
Data  management  and  analysis  were  performed  using  SPSS  software  (SPSS  Inc., 
Chicago, IL, USA) and expressed as mean ± one standard deviation for continuous variables, 
and  as  percentages  for  categorical  variables.  In  all  studies,  variable  without  normal 
distribution are presented as medians and interquartile ranges, and their logarithmic values 
were  used  for  parametric  statistics.  Between-group  comparisons  were  made  by  unpaired 
Student’s t-test or analysis of variance (with Ryan-Einot-Gabriel-Welsch F post-hoc test) to 
determine differences in continuous variables, as appropriate, and  χ2 statistics, determine 
differences  in  categorical  variables.  Differences  between  groups  were  also  assessed  by 
analysis  of  covariance  (with  Sidak  post-hoc  test)  or  binary  logistic  regression  analysis, 
adjusting  for  significant  confounders.  Two-tailed  p<0.05  was  considered  statistically 
significant.
Specifically, in the  S1, logistic regression analysis was used to identify whether and 
what classes of medications at the time of the first visit, were associated with uncontrolled 
BP  at  the  end  of  the  follow-up,  after  hierarchically  adjusting  for  gender,  baseline  age, 
smoking status, systolic BP, heart rate, BMI, diabetes, plasma creatinine, fasting glucose, 
triglycerides,  HDL cholesterol  and total  number of antihypertensive drugs (by a forward 
stepwise  procedure  with  p-to-enter  <0.05  and  p-to-remove  ³0.1).  The  same  model  was 
repeated substituting single metabolic variables (BMI, fasting glucose, triglycerides, HDL 
cholesterol) with MetS at the time of the first visit. Logistic regression was repeated after 
adjusting  for  baseline  systolic  BP and  anthropometrics,  metabolic  variables  and  therapy 
detected at the time of the last available visit. Odds of uncontrolled BP in relation to classes 
of drugs used at the time of the last visit were, therefore, evaluated in patients with MetS, 
separately. Odds ratios and 95% confidence interval for covariates are presented. 
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In the  S2, indicator variables were included in all multivariate analyses for the three 
different field centers (Arizona and Oklahoma versus North/South Dakota). The impact of 
relatedness was considered by using standard kinship coefficients (0.25 for parent-offspring, 
0.25 for full siblings, 0.125 for half siblings and 0 for no consanguinity). In multiple linear 
regression analyses, performed to assess the relation with echocardiographic parameters of 
LV geometry and function, kinship coefficient was first entered together with filed center, 
age and sex. In a second block we included a stepwise selection of the following variables: 
systolic  BP,  heart  rate,  percentage of  body fat,  HDL and LDL-cholesterol,  triglycerides, 
eGFR,  UACR  and  antihypertensive  treatment  with  RAS-blockers.  Diabetes  status  was, 
therefore, forced into the model to verify whether an independent effect remained on LV 
geometry or function. Finally, in the last block, fasting plasma glucose was also forced into 
the model. Attention was paid to avoid substantial multicollinearity by setting the greatest 
tolerable variance inflation factor to 2.5. 
In  the  S3,  stroke  event  rates  in  patients  with  or  without  MAC were  displayed  by 
Kaplan–Meier  plots  and  compared  by  log  rank  test.  To  test  whether  prevalent  MAC 
predicted incident ischemic stroke, independently of confounders [130-132], in addition to 
the simple proportional hazards Cox regression models, build by backward procedures (p-to 
enter <0.05, p-to exclude >0.1), time-varying Cox regression models were also performed to 
consider  variation of  the risk factors  over  time before  the stroke event [133].  To ensure 
stability of the Cox regression analyses, models were set to have the ratio of the number of 
covariates to the number of events≤1:10. Thus, all time varying models included: age, in-
treatment systolic BP, AF, and were also adjusted for the following covariates, one at the 
time:  history  of  previous  cerebrovascular  disease,  gender,  in-treatment  LVM  index,  in-
treatment left atrial diameter and in-treatment log UACR. 
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Results
Impact of Metabolic Risk Factors on Blood Pressure Control 
Clinical  and Metabolic Characteristics   of the Study Population 
Among 4,612 hypertensive patients without prevalent CV disease (43% women; mean 
age 53±11years) at the time of the first visit 28% were free of antihypertensive medications. 
Among  treated  patients,  51%  exhibited  initial  BP  ≥140  and/or  90mmHg,  reflecting 
uncontrolled BP. 
At the time of the first visit, obesity was found in 25%, abnormal fasting glucose in 
18% including diabetic patients (8.6% of the total population), high triglycerides in 32% and 
low HDL-cholesterol  in  34% of  the  total  population.  Smoking habit  was  found in  1208 
participants (26%). The number of hypertensive patients with initial MetS was 1,461 (32% 
of study population,  41% women).  Among them, obesity  was present in  55%, abnormal 
fasting glucose in 42% (diabetes in 20%), high triglycerides and/or low-HDL in 70%. 
The proportion of smokers was similar in participants with MetS compared to those 
without MetS (27% versus 26%, p=0.43).
            At  follow-up,  all  4,612 participants  were  treated with antihypertensive 
medications, and, among them, 1,967 had uncontrolled BP, representing 43% of the total 
population. Uncontrolled BP was combined systolic and diastolic in 41%, isolated systolic in 
45%, and isolated diastolic in 14% of cases.
Baseline predictors of follow-up uncontrolled BP
The main initial characteristics of the studied population in relation to the follow-up BP 
control are reported in  Table 1. Compared to patients with follow-up controlled BP, those 
with uncontrolled BP were older,  had higher initial BP, heart rate,  BMI, fasting glucose, 
triglycerides, total cholesterol and serum creatinine levels, with lower HDL cholesterol and 
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eGFR  (all  p≤0.03).  No  significant  difference  was  found  for  smoking  status  among 
participants with or without follow-up uncontrolled BP. At the time of the first visit, patients 
with follow-up uncontrolled BP had a significant higher prevalence of diabetes and MetS 
compared to those with follow-up controlled BP (all 0.03<p<0.0001; Table 1). 








Age (years) 53 ± 10 54 ± 11 0.0001
Systolic BP (mmHg) 141 ± 16 148 ± 18 0.0001
Diastolic BP (mmHg) 90 ± 10 91 ± 10 0.0001
Heart rate (bpm) 74 ± 11 75 ± 12 0.03
BMI (kg/m2) 27 ± 4 28 ± 4 0.0001
Fasting glucose (mg/dL) 98 ± 20 100 ± 24 0.0001
Total cholesterol (mg/dL) 205 ± 38 208 ± 39 0.02
HDL cholesterol (mg/dL) 50 ± 12 49 ± 12 0.004
Triglycerides (mg/dL) 116 (85-160) 123(90-173) 0.0001
Creatinine (mg/dL) 0.95 ± 0.20 0.97 ± 0.21 0.03
eGFR (mL/min/1.73m2) 82 ±18 80 ± 18 0.001
Smokers (%) 27 25 0.09
Diabetes (%) 8 10 0.008
Metabolic Syndrome (%) 28% 37% 0.0001
Table 2 shows that, at the time of the first visit in our outpatient clinic, higher systolic 
BP, BMI, triglycerides and number of antihypertensive medications independently increased 
the probability of uncontrolled BP at the time of final visit (all p≤0.002), without significant 
effect for other covariates, including classes of anti-hypertensive medications. Initial MetS 
was associated with 43% increased probability of uncontrolled BP (OR=1.43 [95%C.I.=1.25-
1.63];  p<0.0001),  independently of baseline systolic  BP, heart  rate,  presence of diabetes, 
plasma creatinine, smoking status and number or type of initial antihypertensive medications 
and statins.
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Table 2 – Independent initial predictors of follow-up uncontrolled BP
Multivariate analysis
Gender, baseline age, heart rate, presence of diabetes, plasma creatinine, fasting glucose, HDL cholesterol,  
smoking status and single classes of antihypertensive medications and statins did not enter the model (all  
p>0.1)
Association of uncontrolled BP with classes of antihypertensive drugs at the 
time of the last visit
At the time of the last available visit, prevalence of MetS and diabetes was 33% and 
12%,  respectively.  Prevalence  of  uncontrolled  BP was  higher  in  participants  with  MetS 
compared to those without MetS (49% versus 40%; p<0.0001) and in diabetic compared to 
non  diabetic  participants  (49%  versus  42%;  p=0.002).  Mean  number  of  prescribed 
antihypertensive medications was significantly higher at follow-up compared to the first visit 
(2.1±0.9 versus 1.3±0.5;  p<0.0001). 
The  number  of  prescribed  medications  progressively  increased  from  the  group  of 
patients with no metabolic risk factors to the group of patients with one, two, three or more 
clustered  risk  factors  (Figure  3;  p  for  trend<0.0001).  Single-medication  therapy  was 
prescribed to  nearly  1/3 of  patients  (31% of total  studied population) and more often in 
hypertensive without MetS (34% versus 24% of those with MetS; p<0.0001). 
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p≤ OR 95% CI for Exp(B)Lower Upper
Systolic BP (x 5 mmHg) 0.0001 1.12 1.10 1.15
BMI (kg/m2) 0.0001 1.03 1.02 1.05
Triglycerides (x 5 mg/dL) 0.003 1.01 1.01 1.02
Number of drugs 0.0001 1.20 1.13 1.27
Results
Figure 3 – Number of antihypertensive according to the number of risk factors 
Diuretics,  RAS-blockers,  calcium-channel  blockers  and  α-blockers  were  prescribed 
more  frequently  in  subjects  with  MetS  than  in  those  without  MetS,  without  significant 
differences for β-blockers prescription (Table 3). Statins were also prescribed more often in 
participants with MetS than in those without MetS (25% versus 22%, respectively; p=0.02). 
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 Table 3 – Type of antihypertensive medications prescribed at the time of the last available 





Diuretics (%) 48 56 0.0001
β-blockers (%) 34 37 0.08
RAS-blockers (%) 76 81 0.0001
Ca++-channel blockers (%) 32 36 0.006
α-blockers (%) 9 10 0.05
We analyzed independent correlates of uncontrolled BP at the time of the last available 
visit. Table 4 shows odds of uncontrolled BP in relation to classes of medications used at the 
time of  the  last  available  visit,  adjusting for  significant  confounders.  Initial  systolic  BP, 
female gender with older age, heart rate, BMI, plasma creatinine, triglycerides and higher 
number of antihypertensive medications at the time of the last visit were all independently 
associated with uncontrolled BP (all  0.02<p<0.0001).  Among classes of antihypertensive 
medications, diuretics and RAS-blockers were less likely to be prescribed when BP remained 
uncontrolled  (p≤0.002),  whereas  no  significant  influence  was  observed  for  β-blockers, 
calcium-channel  blockers  or  α-blockers.  Prescription  of  statins  reduced  by  21%  the 
probability  of  uncontrolled  BP (p=0.003;  Table  4).  Less  prescription  of  diuretics,  RAS-
blockers and Statins were still related to uncontrolled BP (all p≤0.002), also when analysis 
was adjusted for the presence of MetS, which confirmed a 35% higher risk of uncontrolled 
BP (OR=1.35 [95% C.I.= 1.18-1.54], p<0.0001).  
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 Table 4 –  Independent correlates of uncontrolled BP in the whole population sample at the 
time of last available visit
p≤ OR 95% CI for Exp(B)Lower Upper
Age (year) 0.002 1.01 1.00 1.02
Female gender 0.02 1.18 1.02 1.36
Initial Systolic BP (x 5 mmHg) 0.0001 1.10 1.09 1.12
Heart Rate (bpm) 0.0001 1.02 1.01 1.03
BMI (kg/m2) 0.0001 1.04 1.03 1.06
Plasma Creatinine (x mg/dL ) 0.001 1.64 1.23 2.20
Triglycerides (x5 mg/dL ) 0.0001 1.01 1.01 1.02
Number of drugs 0.0001 1.27 1.16 1.39
Diuretics (%) 0.0001 0.73 0.62 0.86
RAS-blockers (%) 0.002 0.77 0.66 0.91
Statins (%) 0.003 0.79 0.68 0.92
Multivariate analysis including data detected at the time of the last available visit (with the exception of  
baseline systolic BP)
Diabetes,  fasting glucose,  HDL cholesterol,  smoking status,  β-blockers,  calcium-channel  blockers and α-
blockers did not enter the model (all p>0.1)
Evaluation of anti-hypertensive therapy in relation to uncontrolled BP was also carried 
out in the 1522 hypertensive patients with MetS (Tables 5). In this subgroup, uncontrolled 
BP confirmed to be independently associated with higher baseline systolic BP and higher 
number of medications at the time of the last visit (p<0.0001). Prescriptions of diuretics and 
RAS-blockers were again associated with 28% reduced probability of uncontrolled BP in 
hypertensive patients with MetS, independently of other confounders (both p<0.03). 
 Tables 5 –  Independent correlates of Poor BP control at the time of last available visit in 
hypertensive patients with metabolic syndrome
p≤ OR 95% CI for Exp(B)Lower Upper
Initial Systolic BP (x 5 mmHg) 0.0001 1.12 1.10 1.15
Heart Rate (bpm) 0.0001 1.02 1.01 1.03
Number of drugs 0.0001 1.34 1.16 1.56
Diuretics (%) 0.02 0.72 0.55 0.94
RAS-blockers(%) 0.03 0.72 0.54 0.97
Multivariate analysis including data detected at the time of the last available visit (with the exception of  
initial systolic BP)
Gender,  age,  BMI,  diabetes,  plasma  creatinine,  fasting  glucose,  tryglicerides,  smoking  status, HDL 
cholesterol,  β-blockers, calcium-channel blockers, α-blockers and statins  did not enter into the model (all  
p>0.1)
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Impact of Diabetes on Cardiovascular Phenotype in Adolescents 
and Young Adults
Clinical   and Metabolic Characteristics of the Study Population 
Among the 1,624 adolescent and young adult participants without reported clinical CV 
disease: 1,146 (71%) had normal fasting glucose (NFG), 299 (18%) had IFG and 179 (11%) 
had DM. Sixty six percent were obese and 19% had arterial hypertension. Mean reported 
duration of DM was 4.7 years.  Insulin treatment was reported in 43 diabetic participants 
(24%), while 95 participants (53%) were on oral antidiabetic therapy.
Table 6 shows that age, BMI, body fat, waist girth and waist-to-hip ratio progressively 
increased from NFG to DM. IFG and DM participants had similar prevalence of obesity and 
mean values of BP, both significantly higher than NFG. Prevalence of arterial hypertension 
and antihypertensive treatment progressively increased from NGF to DM. Participants with 
DM had higher heart rate than the other groups (all p<0.05). Prevalence of smokers was 
similar between groups.  Fasting glucose,  triglycerides and LDL cholesterol  progressively 
increased from NFG to DM, while participants with IFG and DM had lower HDL compared 
to  those  with NFG.  Participants  with  DM had significantly  lower plasma creatinine  and 
significantly  higher  eGFR,  UACR  and  albuminuria  compared  to  the  other  groups  (all 
p<0.0001). 
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Age (years) 25.3±7.4 28.6±7.7* 32.1±5.9*† 0.0001
Gender (% women) 60% 47%* 58%† 0.0001
BMI (kg/m2) 30.6±8.0 35.9±8.6* 38.1±10.2*† 0.0001
Body fat (%) 36±11 40±11* 43±9*† 0.0001
Waist circumference (cm) 98±18 112±19* 117±19*† 0.0001
Waist-to-hip ratio 0.88±0.08 0.92±0.07* 0.95±0.08*† 0.0001
Obesity (%) 61% 78%* 83%* 0.0001
Systolic BP (mmHg) 116±12 121±13* 122±18* 0.0001
Diastolic BP (mmHg) 73±11 79±11* 80±11* 0.0001
Arterial Hypertension (%) 11% 25%* 65%*† 0.0001
Antihypertensive therapy (%) 2% 6%* 25%*† 0.0001
Heart rate (bpm) 66±11 67±11 74±12*† 0.0001
Smokers (%) 35% 37% 39% 0.441
Fasting Glucose (mg/dL) 89 (84-94) 105 (102-112) * 182 (137-280)*† 0.0001
Triglycerides (mg/dL) 111 (82-158) 142 (103-197)* 196 (145-295)*† 0.0001
LDL cholesterol (mg/dL) 93±27 98±29* 109±33*† 0.0001
HDL cholesterol (mg/dL) 51±13 48±13* 46±13* 0.0001
Creatinine (mg/dL) 0.8 (0.7-0.9) 0.8 (0.7-0.9) 0.6(0.6-0.8)*† 0.0001
eGFR (mL/min/1.73m2) 109±23 109±23 129±34*† 0.0001
UACR (mg/g) 6 (4-11) 7 (4-13) 17 (9-62)*† 0.0001
Albuminuria (%) 8% 12%* 41%*† 0.0001
p for analysis of variance
Ryan-Einot-Gabriel-Welsch F post-hoc analysis
* = p<0.05 versus NFG
† = p<0.05 versus IFG
Cardiovascular Phenotype
LV Geometry
Table  7 shows  comparisons  of  echocardiographic  parameters  by  univariate  and 
multivariate analyses. After adjustment for age, sex, kinship coefficient, field center, systolic 
blood pressure and percent of body fat, there was no significant between-group difference in 
left atrial dimension or LV chamber diameter. Participants with DM had higher RWT than 
both IFG and NFG, independently of covariates. Consequently concentric LV geometry was 
more prevalent in participants with DM (7.3% versus 3.7% NFG, and 3.1% IFG, p=0.03). 
After adjustment for covariates,  odds of concentric LV geometry were significantly greater 
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in participants with, compared to those without DM (OR=2.15; 95% CI=1.06-4.36, p=0.03). 
Table  7  shows  that  absolute  and  indexed  values  of  LVM  were  progressively  higher  in 
participants  with  IFG or  DM,  than  in  those  with  NFG,  independently  of  differences  in 
potential confounders. The prevalence of clear-cut LVH was 17% in IFG and 20% in DM 
participants, both significantly higher compared to 12% in NFG participants (p<0.05). The 
prevalence of  LVM exceeding the individual age-specific value predicted by stroke work, 
gender and height2.7 (inappropriate LVM), was higher (25%) in participants with DM than in 
those without DM (13% in NFG and17% in IFG participants, OR=1.63; 95%CI=1.08-2.44, 
adjusted p=0.02).






(N=179) p ≤ adjusted  p≤
LA diameter (cm) 3.5±0.4 3.7±0.4 3.8±0.4 0.0001 0.776
LV diameter (cm) 5.4±0.4 5.4±0.4 5.4±0.5 0.0001 0.261
RWT 0.31±0.05 0.32±0.04 0.34±0.04*† 0.0001 0.003‡
LVM (g) 145±37 166±41* 169±43* 0.0001 0.009
LVM index (g/m2.7) 36±8 39±9* 41±9* 0.0001 0.014
Stroke index (ml/m2.04) 27±4 28±4 28±4 0.001 0.919
PP/SV (mmHg/mL/beat) 0.55±0.14 0.52±0.14 0.52±0.15 0.003 0.810‡
Ejection Fraction% 62±4 61±4* 62±4 0.001 0.022
Stress-corrected
endocardial FS (%)
99±8 100±8 100±9 0.246 0859§
Stress-corrected
midwall FS (%)
101±9 99±8* 98±9* 0.0001 0.003§
E velocity (cm/sec) 92±16 91±16 89±19 0.038 0.579
A velocity (cm/sec) 54±14 59±14* 66±16*† 0.0001 0.0001
E/A ratio 1.8±0.5 1.6±0.5 1.4±0.4*† 0.0001 0.0001
Deceleration time (ms) 212±36 219±40 223±38 0.0001 0.197
IVRT (ms) 76±10 77±11 81±11*† 0.0001 0.012
Atrial filling fraction 0.24±0.07 0.26±0.07 0.31±0.09*† 0.0001 0.0001
p for analysis of variance
p adjusted by analysis of covariance  for age, gender, systolic BP, body fat, field center and kinship 
coefficients
Sidak post-hoc analysis
* = p adjusted<0.05 versus NFG
† = p adjusted<0.05 versus IFG
‡ = adjustment excluded age
§ = adjustment excluded systolic BP
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LV Systolic and Diastolic Function and Systemic  Hemodynamics  
As shown in Table  7,  after  adjusting for  age,  sex,  kinship coefficient,  field center, 
systolic blood pressure and percent of body fat, no significant differences were found for 
stroke index or PP/SV. Ejection fraction was lower in participants with IFG, due to their 
greater wall  stress,  as  shown by the  normal  stress-corrected endocardial  FS.  In  contrast, 
stress-corrected  midwall  FS  (an  afterload-geometry  independent  myocardial  function 
parameter)  was  significantly  lower  in  participants  with  DM  and  IFG than  in  NGT  (all 
adjusted p<0.05). All Doppler parameters of diastolic function differed significantly among 
groups in univariate analysis, showing a trend towards abnormal relaxation associated with 
worsening  of  glycemic  control  (all  p<0.05).  After  adjusting  for  covariates,  however,  no 
significant differences were detected for mitral E velocity or deceleration time. Mitral A 
wave velocity was progressively higher from NFG to DM. Compared to the other groups, 
participants with DM had lower E/A ratio, higher IVRT and greater  atrial filling fraction. 
Differences in Doppler diastolic parameters were confirmed also adjusting for heart rate. 
Differences in echocardiographic parameters were not substantially altered after further 
control  for  plasma  creatinine,  UACR,  RAS-blockers  treatment  and  duration  of  DM  in 
addition to age, sex, kinship coefficient, field center, systolic BP and percent of body fat. 
No significant differences were found between diabetic participants on oral therapy and 
those on insulin treatment. In addition, all results reported in table  7 were also confirmed 
after  the  exclusion  of  the  43  DM participants  on  insulin  treatment.  Finally,  we  did  not 
detected  any  significant  differences  in  echocardiographic  parameters  between  diabetic 
participants with or without good glycemic control (Hb1Ac<7%).  
Independent Correlates of LV Geometry and Function 
Multiple linear regression analyses were performed to evaluate independent correlates 
of LV geometry and function in the whole population. Table 8 shows multiple-R values and 
standardized  β-coefficients  of  variables  significantly  associated  with  the  most  relevant 
echocardiographic parameters. As shown in this Table, greater body fat was independently 
related to increased LVM index and RWT, reduced stress-corrected FS and prolonged LV 
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relaxation (lower E/A ratio and longer IVRT). Among metabolic parameters, low HDL was 
associated with increased LVM index,  RWT and decreased stress-corrected midwall  FS, 
while high LDL was related with low E/A ratio. eGFR was related to increased LVM index, 
RWT and ejection fraction. Albuminuria was significantly related to increased LVM index. 
No  independent  impact  was  detected  for  kindship  coefficients,  plasma  triglycerides  and 
RAS-blockers therapy (or any antihypertensive treatment). Diabetes remained significantly 
associated with high LVM index, low ejection fraction, low stress-corrected midwall FS and 
prolonged IVRT, without significant correlation with RWT or E/A ratio (Table 8). 

















Age (years) 0.21§ 0.23§ 0.11§ -0.10§ -0.39§ 0.27§
Gender (Male vs Female) 0.22§ NS -0.20§ -0.22§ NS 0.07*
Systolic BP(mmHg) 0.19§ 0.10§ NS NS -0.05* NS
Heart rate (bpm) -0.08† 0.10§ -0.07* -0.16§ -0.42§ -0.11§
Body fat (%) 0.38§ 0.16§ NS -0.14§ -0.08* 0.11†
HDL cholesterol (mg/dL) -0.08† -0.09* NS 0.07† NS NS
LDL cholesterol (mg/dL) NS NS NS NS -0.06† 0.08†
Triglycerides (mg/dL) NS NS NS NS NS NS
eGFR(mL/min/1.73m2) 0.10§ 0.08† 0.14§ NS NS NS
UACR (mg/g) 0.08† NS NS NS NS NS
RAS-blockers (Yes vs No) NS NS NS NS NS NS
Diabetes (vs NFG) 0.08† NS -0.07* -0.08† NS 0.08†
Multiple R 0.55 0.40 0.28 0.32 0.66 0.37
Models adjusted also for field center and kindship coefficients
* = adjusted p<0.05; † = adjusted p <0.01; § = adjusted p<0.0001 
NS = not statistically significant (adjusted p>0.05)
When fasting plasma glucose was forced into the model, a significant effect of diabetes 
remained only for LVM index (β=0.10, p<0.05), whereas high glucose was associated with 
low ejection fraction (β=-0.13, p<0.01), low stress-corrected midwall FS (β=-0.10, p<0.05) 
and  prolonged  IVRT  (β=0.12,  p<0.01).  In  a  sub-analyses  performed  selectively  in 
participants without DM, high HOMA index was independently related to high LVM index, 
increased RWT and lower stress-corrected midwall FS (all adjusted p<0.05). In DM, Hb1Ac 
and duration of DM were not independently related to LV geometry and function.
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Impact of Mitral Annulus Calcification on Incident Stroke 
Clinical and Metabolic Characteristics   of the Study Population 
Among  the  939  hypertensive  patients (23%  with  obesity  and  11%  with  diabetes) 
included in the present study, 458 (49%) had MAC present on the echocardiogram. Table 9 
shows baseline clinical and metabolic characteristic of the LIFE participants with or without 
MAC.
 





Age (years) 68 ± 7 65 ± 7 0 .0001
Women (%) 47 37 0.001
African-American ethnicity (%) 16 12 0.06
BMI (kg/m2) 28 ± 5 27 ± 4 0.12
Systolic BP (mmHg) 175 ± 14 172 ± 15 0.001
Diastolic BP (mmHg) 98 ± 10 99 ± 8 0.08
Heart rate (bpm) 69 ± 12 67 ± 12 0.006
Fasting glucose (mg/dL) 111 ± 46 106 ± 38 0.07
History of diabetes (%) 13 10 0.09
Total cholesterol (mg/dl) 231 ± 45 230 ± 42 0.84
HDL cholesterol (mg/dl) 59 ± 18 59 ± 17 0.99
Serum creatinine (mg/dl) 1.0 ± 0.2 1.0 ± 0.3 0.80
eGFR (mL/min/1.73m2) 72 ± 17 73 ± 16 0.08
UACR (mg/g) 16 (6-47) 9 (4-28) 0.0001
Albuminuria (%) 30 21 0.005
History of previous CV disease (%) 28 23 0.08
History of previous stroke/TIA (%) 9 8 0.55
Smokers (%) 21 19 0.57
Treatment with Losartan (%) 50 50 1.00
Treatment with Aspirin (%) 31 23 0.01
Participants with MAC were older, had higher baseline systolic BP and UACR and 
included more women and patients with albuminuria (all p<0.01). No significant differences 
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were detected between groups in prevalence of African-American ethnicity, mean baseline 
BMI,  diastolic  BP,  fasting  glucose,  history  of  diabetes,  total  or  HDL cholesterol,  serum 
creatinine, eGFR, history of previous CV disease or smoking status. Losartan or atenolol 
treatment were given in the same proportion in both groups (all p>0.05), while participants 
with MAC were prescribed to take more often aspirin than those without MAC (p=0.01).
Combined prevalent and incident AF during the study conduct was significantly higher 
in subjects with (9%) compared to those without MAC (5%; p=0.04).
Table  10 shows that participants with MAC had larger baseline left  atrial diameter, 
LVM index and higher prevalence of echocardiographic LVH (all p<0.01). No significant 
differences were found in relative wall thickness, ejection fraction, stress-corrected midwall 
FS or PP/SV between groups (p>0.05).  
Table  10  –  Baseline  echocardiographic  parameters  of  hypertensive  participants  with  or 
without MAC 





Left atrial diameter (cm) 4.0 ± 0.5 3.8 ± 0.6 0 .0001
LVM index (g/m2.7) 58 ± 13 55 ± 12 0.0001
LVH (%) 77 68 0.002
Relative wall thickness 0.41 ± 0.07 0.41 ± 0.06 0.70
Ejection Fraction (%) 61 ± 9 61 ± 8 0.60
Stress corrected-Midwall FS (%) 86 ± 12 86 ± 11 0.90
PP/SV (mmHg/mL) 1.1 ± 0.3 1.0 ± 0.3 0.06
Risk of I  ncident Ischemic Stroke  
During a mean follow-up of 4.8 years, a total of 58 ischemic stroke events occurred. 
Kaplan–Meier  curves  (Figure  4)  illustrate  that  the  incidence  of  stroke  was  significantly 
higher in treated hypertensive participants with MAC (9% versus 4% in those without MAC, 
log rank =9, p<0.01). 
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Figure  4 –  Kaplan-Meier plot of rate of incident stroke over a mean follow-up of 4.8 years 
related to presence or absence of MAC in treated hypertensive patients
MAC was confirmed to  be  related to  the  risk of  ischemic stroke (HR= 1.78,  95% 
C.I.:1.02-3.11, p=0.04), independently of age (HR= 1.08/year, 95% C.I.:1.04-1.13, p<0.01), 
baseline systolic BP (p>0.1), AF (HR= 3.01, 95% C.I.:1.59-5.72, p<0.01), and history of 
previous cerebrovascular disease (p>0.1).    
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Table 11 shows significant predictors of incident ischemic stroke by time-varying Cox 
regressions.  Prevalent  MAC  was  associated  with  at  least  a  1.78-fold  increased  risk  of 
incident ischemic stroke over 4.8 years of follow-up, independent of the common covariates 
of  age,  time-varying systolic  BP and AF,  and the  additional  inclusion,  one at  a  time in 
separate  models,  of  previous  cerebrovascular  disease,  male  gender,  time-varying  LVM 
index, left atrial diameter, or log UACR (p<0.05). 
Table  11– Independent association between MAC and incidence  of  ischemic stroke over a 
mean  of  4.8  years  of  randomized  study  treatment  in  multivariate  time-dependent  Cox 
regression analysis
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___ ___ 1.02(1.01-1.04)* ___ ___
Time-varying






___ ___ ___ ___ 1.75(1.15-2.67)**
Models are adjusted for time variation of variables before the stroke event. Hazard Ratio (95% Confidence  
Interval) are reported for significant variables in the models
* =  p<0.05; ** = p<0.01; † = not significant (p>0.05); ___ = not included into the model
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Finally, in additional models MAC was also confirmed as an independent predictor of 
ischemic stroke (HRs from 1.81 to  2.01,  0.04<p<0.01),  when time-varying models  were 
adjusted  also  for  time-varying  diastolic  BP  (HR=  1.07,  95%  C.I.:1.03-1.10,  p<0.  01), 
African-American  ethnicity,  time-varying  fasting  glucose,  time-varying  eGFR  or  time-
varying PP/SV, respectively (all p>0.05, data not shown).
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Discussion
Metabolic  CV  risk  factors  concur  to  determine  CV  disease,  through  a  direct 
unfavourable impact on incidence of disease and also through their  adverse influence on 
efficacy  of  therapy  [17-22] and  on  cardiovascular  phenotype  [32-41],  which  in  turn 
predispose to development of overt  disease  [32]. The comprehensive scope of this Ph.D. 
thesis was to assess the impact of metabolic risk factors on the efficacy of antihypertensive 
therapy and on prevalence and incidence of preclinical and clinical CV disease, evaluating 
new predictors of clinical disease.
Impact of Metabolic Risk Factors on Blood Pressure Control 
As demonstrated in  Study 1,  in a large population of outpatient clinical hypertensive 
patients, reflecting the general clinical practice [85], although the effort to reduce and control 
BP is substantial, and a large number of medications is often prescribed, a large proportion 
of patients (43%) did not achieve BP control. This discouraging data is in line with diffuse 
evidence in different populations that BP control in clinical practice is largely insufficient 
[30,31,134,135]. We and others have previously reported that prevalence of uncontrolled BP 
increases with the number of metabolic risk factors despite the use of greater number of 
antihypertensive drugs [22-24], even if BP response to therapy seems not to be affected by 
presence of MetS [136]. The specific scope of the S1 was to assess whether the BP response 
to  different  classes  of  antihypertensive  drugs  could  help  understanding  the  apparent 
resistance to  treatment  associated  with  clusters  of  metabolic  risk factors.  The Campania 
Salute network differs from clinical trials in that it provides a rare opportunity to validate 
therapeutic strategies in an unbiased real-life population [85]. We found that when combined 
metabolic CV risk factors were taken into account at the time of initial visit in our tertiary 
care center, the classes of antihypertensive drugs used as initial therapy did not influence the 
probability of uncontrolled BP at the time of last visit. Rather, obesity and the associated 
clustering of risk factors might offset the efficacy of initial therapy. Thus, at the time of first 
presentation in our Hypertension Center, type of antihypertensive therapy had little influence 
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on achievement of BP controls over time. The discontinuity and variability in medical care in 
these patients at the time of the onset of the study might have influenced these results. 
However, after at least one year of strict office controls in our Hypertension Center, 
when  management  of  arterial  hypertension  was  obtained  following  guidelines 
recommendations [29,65,96], the therapeutic response of these patients appears influenced 
also by the choice of specific classes of antihypertensive drugs. In particular, utilization of 
diuretics  and  RAS-blockers  resulted  in  improved  BP  control  also  when  the  impact  of 
clustered CV risk factors and other classes of antihypertensive medications was taken into 
account. Diuretics and/or RAS-blockers reduced the odds of uncontrolled BP at the last visit, 
and this was evident both in the whole population sample and in the sub-population with 
MetS,  possibly  suggesting  an  inadequate  rate  of  prescription  of  these  two  classes  of 
medications. 
We do not have yet complete available data on variation of therapy during the follow-
up, and we could not evaluate the impact of modification of antihypertensive therapy with 
addition and/or substitution of specific classes of drugs by time varying analysis, and further 
studies should be performed to assess this important issue. Thus, our analysis does not allow 
us to draw cause-effect conclusions, since the association of uncontrolled BP with single 
classes of medications is influenced by the cross-sectional nature of the study. We observed 
that  the  higher  number  of  prescribed  drugs  in  the  sub-group  with  MetS,  was  in  fact 
negatively associated with BP control, reflecting the greater, albeit often unsuccessful, effort 
to control BP in these patients. 
The evidence that diuretics were less likely to be prescribed when BP was uncontrolled 
in hypertensive patients, including those with MetS, suggests that diuretics should probably 
be prescribed even more frequently than found in this analysis, to improve control of BP in 
populations referred to tertiary care centers. The reason for this potential inadequate diuretic 
prescription is  likely mostly but not univocal [137-139],  the concern that  diuretics  might 
aggravate metabolic impairment in patients with high risk of diabetes [139-141].
 Actually,  BP lowering induced by  diuretics  has  shown to significantly  reduce CV 
events [139,142], even in patients with MetS, in spite of higher incidence of diabetes [143]. 
We previously reported that uncontrolled BP is a significant predictor of incident diabetes in 
the Campania Salute network [84], independently of type of antihypertensive therapy, and 
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we also did not find any independent association between diuretics and incident diabetes, 
once other metabolic risk factors were taken into account. However, since diabetes is a major 
risk factor for micro and macro-vascular CV complications, further studies are needed to 
determine whether the potential advantages of more intensive therapy with diuretics on BP 
control might balance possible unfavourable metabolic effects, especially in patients with 
MetS. 
In contrast  to the debate on antihypertensive treatment with thiazide-type diuretics as 
first line monotherapy, there is currently large consensus about use of RAS-blockers in the 
management of such hypertensive patients, especially in patients with MetS, where they are 
considered  treatment  of  choice,  due  to  their  beneficial  effect  on  insulin  sensitivity  and 
glycemic control [65,144]. Activation of the RAS system has been associated with obesity 
and insulin resistance,  and has been proposed to provide a pathophysiologic link among 
obesity, diabetes and hypertension [144-146]. The present results confirm the positive impact 
of RAS-blockers on rate of BP control, mainly evident in MetS. 
Even interesting and somewhat unexpected is the evidence that prescription of statins 
reduced the probability of uncontrolled BP in the whole population sample, but not in the 
sub-population with MetS (in which prescription were much more frequent), independently 
of antihypertensive treatment. These results are consistent with recent studies showing slight 
but significant antihypertensive effect of statins,  which appear to be independent of their 
cholesterol lowering action [147-149]. There are several mechanisms through which statins 
may affect BP [149],  through their  favourable effects on endothelial function [150],  their 
interaction with the renin–angiotensin system [151], and their ability to affect large artery 
compliance [152]. 
Impact of Diabetes on Cardiovascular Phenotype in Adolescents  
and Young Adults
The second  aim of the Ph.D. project was to assess the impact of metabolic risk factor on 
presence  of  preclinical  CV disease  in  young  apparently  healthy  subjects  (Study  2).  The 
increasing  prevalence  of  obesity  and subsequently  incidence  of  pre-diabetes  and DM in 
young people in different countries represents a major public health concern because of the 
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risk CV complications [51-59]. Accordingly, the  S2 focused specifically on the impact of 
impaired  glycemic  metabolism  on  the  CV  phenotype  in  young  individuals.  This  study 
provides the first comprehensive comparison of LV structure and function between diabetic, 
pre-diabetic  and  normoglycemic  participants  of  a  large  population-based  sample  of 
adolescents and young adults with high prevalence of obesity, but free from prevalent CV 
disease. As demonstrated, despite the young age, individuals with DM  exhibited features 
associated with increased CV risk, including LV hypertrophy, concentric LV geometry and 
preclinical  systolic  and  diastolic  dysfunction. Moreover,  participants  with  pre-diabetes 
(measured by IFG) also had a significantly higher prevalence of LVH than participants with 
NFG, reflecting important target organ damage already present at an early stage of impaired 
glucose metabolism. This observation is important in view of the strong relation between 
LVH  and  adverse  CV  outcomes  [153]  and  provides  a  strong  rationale  for  targeting 
prevention strategies in this subpopulation. Although participants with DM and IFG were 
more often obese and hypertensive, these two conditions were not sufficient to explain the 
identified  CV  abnormalities  associated  with  diabetes,  which  remained  an  independent 
correlate of increased LV mass, reduced LV systolic function and abnormal LV relaxation. 
Thus, our results suggest that diabetes augments the already demonstrated adverse impact of 
obesity and hypertension on CV phenotype in the young participants of the Strong Heart 
Study [43-45]. Additionally, in DM, the level of increased LVM substantially exceeds the 
needs  to compensate for  cardiac  workload,  resulting in a  markedly higher prevalence of 
inappropriate LVM. This finding  also reinforce the view that in DM LVH may not only be a 
response to substantially increased hemodynamic load, related to obesity or hypertension, 
but may also reflect neurohormonal and metabolic stimuli to LV growth. 
Another characteristic of the emerging CV phenotype in DM in adolescents and young 
adults is the presence of geometry-related LV functional alterations, also identified in pre-
diabetes. Early LV systolic dysfunction, associated with DM and IFG, could be detected by 
stress-corrected  midwall  FS,  but  not  by  measures  of  LV systolic  function  taken  at  the 
endocardial  level,  like endocardial  FS and ejection fraction,  which are both substantially 
more  influenced  by  the  abnormalities  in  LV  geometry,  documented  by  the  progressive 
increase  in  RWT [128].  The  slight  reduction  in  ejection  fraction  found in  IFG was  not 
confirmed by stress-corrected endocardial FS, demonstrating an afterload mismatch (higher 
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systolic BP without adequate compensation in LV geometry) in this subgroup. Abnormality 
in  LV filling,  characterized  by  active,  energy-consuming  relaxation  (low  E/A  ratio  and 
prolonged IVRT) were also evident,  independent of major covariates.  These findings are 
particularly notable because these alterations might mediate, at least in part, the documented 
increased  risk  for  heart  failure  associated  with  DM,  also  in  the  absence  of  myocardial 
infarction [64,154].
Thus,  the  cardiovascular  phenotype  emerging  from  our  analysis  is  similar  to  that 
reported  in  the  description  of  the  so  called  “diabetic  cardiomyopathy”  in  elderly  adults 
[62,63]: increased LV mass with tendency to concentric LV geometry together with subtle 
systolic  and  diastolic  dysfunction.  Several  mechanisms  have  been  implicated  in  the 
pathophysiology of diabetic cardiomyopathy. Of these, hyperinsulinemia, dysregulation of 
adipokine  secretion,  increases  in  circulating  levels  of  inflammatory  mediators,  aberrant 
activation  of  rennin-angiotensin-aldosterone  system  concur  to  increased  oxidative  stress 
damage,  interstitial  accumulation of advanced-glycated end-products,  myocardial  fibrosis, 
small vessel disease, and cardiac autonomic neuropathy [155-157].
Unfortunately, in this cohort, Hb1Ac was measured only in diabetic participants and 
could not be analyzed in the whole population. In the sub-analyses performed in the diabetic 
participants, Hb1Ac did not exhibit an independent impact. However, fasting plasma glucose 
could  be  used  in  the  whole  population  as  a  surrogate  of  metabolic  control  of  glucose 
homeostasis providing a wider range of variability. Under this assumption, the final model of 
the  multiple  regression  analysis,  showing  associations  between  metabolic  and 
echocardiographic variables, strongly suggests that at least a substantial part of the subtle LV 
systolic and diastolic dysfunction detected in the young diabetic participants of the Strong 
Heart Study is related to their metabolic control. 
Despite the young age, diabetic participants exhibited dyslipidemia and kidney function 
alterations, including a tendency to glomerular hyperfiltration and early proteinuria. These 
metabolic  alterations  are  independently  associated  with  LV  geometry  and  functional 
parameters  and  thus  might  also  contribute  to  the  adverse  CV phenotype  found  in  DM, 
through  mechanisms  that  might  involve  microvascular  changes,  inflammation,  early 
atherosclerotic disease and hormonal dysregulation.
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Some limitations  of  this  study  merit  consideration.  Despite  the  high  prevalence  of 
obesity, the number of participants with diabetes was relatively small, because of the young 
average age of this cohort. Incidence of diabetes, which requires a number of years of insulin 
resistance and resultant pancreatic overstimulation, peaks in the fourth decade of life in the 
SHS population [158]. The Strong Heart Study is a population of North American Indians 
with high prevalence of obesity and diabetes that at the beginning of the study was greater 
than in the general United States population. However, results of the Strong Heart Study are 
increasingly applicable  to other populations of different ethnicities given the epidemics of 
obesity, diabetes and other metabolic abnormalities in all Western populations [159]. 
Finally, although North American Indians participating in the Strong Heart Study have 
been extensively documented to have high prevalence of obesity and type 2 diabetes, we 
could not completely exclude possible misclassification of participants with type 1 DM and 
concomitant obesity,  since we did not measure antibodies or  C-peptide levels.  However, 
when we compared the 37 DM participants with reported insulin therapy with those without 
insulin treatment, we did not find any significant differences, and results of this study were 
all  confirmed  also  in  a  separate  analysis,  excluding  the  DM  participants  under  insulin 
treatment. 
Impact  of  Mitral  Annulus  Calcification  on  Incident  Ischemic 
Stroke
The last part of the Ph.D. thesis was focused on evaluation of MAC as a new predictor of 
ischemic stroke in high risk treated hypertensive patients (Study 3). We demonstrated for the 
first  time  that  MAC  was  independently  associated  with  incident  ischemic  stroke  in  a 
population of treated high risk hypertensive patients with electrocardiographic signs of LVH, 
thus adding to current knowledge in the field.  Previous studies have reported significant 
association between MAC and stroke, but such findings have not been uniform. Similar to 
our results, MAC was found to be independently associated with the risk of stroke in two 
population-based studies from the Framingham Heart Study [71] and the Strong Heart Study 
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[72], but only marginally among the elderly subjects of the Cardiovascular Health Study [73] 
and in the Northern Manhattan Study [70] a population substantially different in ethnicity, 
with ~80% Hispanic or African-American participants. The LIFE study population, similar 
to  the  population  based  Framingham  Heart  Study  cohort,  included  predominantly 
Caucasians,  on average younger than participants  in the  Cardiovascular Health Study. In 
contrast with the population based Framingham Heart Study and Strong Heart Study cohorts, 
however, the LIFE population comprised exclusively hypertensive patients with a very high 
risk profile.
Several  explanations  may  account  for  the  association  between  MAC  and  incident 
ischemic stroke. MAC is associated with the same clinical risk factors that lead to subclinical 
and  then  to  clinical  atherosclerosis  [64-68],  and  may  reflect  the  integrated  strength  and 
duration of exposure to these risk factors. Thus, MAC might represent an alternative marker 
of  atherosclerotic  disease  and,  hence,  of  risk  for  cerebrovascular  disease,  a  possibility 
strongly supported by the evidence of  associations of MAC with coronary artery disease 
[160] and carotid atherosclerosis [76-80], a prognostic marker for stroke more potent than 
MAC in unselected population samples including hypertensive and normotensive subjects 
[82]. Unfortunately, carotid ultrasound was not performed systematically in the LIFE study 
and we could not assess whether MAC retained its prognostic impact also independently of 
presence  of  carotid  plaque.  However,  the  prevalence  of  carotid  plaque  in  hypertensive 
patients is very high. From the Campania Salute network we recently demonstrated that more 
than 58% of unselected hypertensive patients without clinical CV disease had carotid plaques 
that were detectable on carotid ultrasound examination, with a clear increase in prevalence 
according to increasing arterial stiffness measured by PP/SV [161]. In the LIFE patients, we 
did not detect significant differences in PP/SV or lipid profile, in relation with the presence 
or the absence of MAC, making it unlikely that the statistical effect of MAC could be offset 
by the possible presence of carotid plaque (likely to be present in a majority of these  high 
risk patients).  
MAC was found in  about  half  of  the  hypertensive  patients  included in  the  present 
study, exceeding the prevalence previously described in population-based samples [70-73], 
reflecting the high risk CV profile of the LIFE patients. In the LIFE population also 72% had 
LVH on the echocardiogram and 25% had albuminuria at baseline in the study, both known 
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markers of  high risk for  stroke [162,112].  However,  generalization of our results  to less 
selected groups of hypertensive patients should be done with caution. 
In  hypertension,  atrial  fibrillation  is  associated  with  high  risk  for  ischemic  stroke. 
[109,131]. As demonstrated, the association between MAC and incident ischemic stroke was 
also independent of AF as well as independent of  other traditional stroke-risk markers like 
LVM  [153,162],  left  atrial  size  [132],  and  UACR  [112],  both  at  baseline  and  during 
treatment. Thus, MAC emerges as a strong predictor of ischemic stroke independent of more 
established  echocardiographic  and  laboratory   prognostic  stroke  markers.  This  was  also 
confirmed in analyses using time-varying covariates, which reinforce the evidence that MAC 
remains associated with incident stroke even with updating of the status of covariates during 
follow  up.  These  findings  strongly  suggest  that  the  importance  of  MAC  to  refine 
quantification of the risk of stroke might exceed what can be merely considered as a marker 
of atherosclerotic disease, and additional validation in less selected hypertensive populations 
should be performed. 
Another interesting possibility is that MAC may be a direct source of embolic stroke. 
This  has  been  suggested  by  autopsy  study  [163] and various  previous  reports  that  have 
documented  mobile  calcific [164]  or  thrombotic  debris  attached  to  irregularities  on  the 
endocardial surface of the annular calcification [165], often in the setting of frank ulceration 
of annular calcium, in patients with cerebral embolism. Given the small number of ischemic 
strokes, we did not have statistical power to address ischemic stroke subtypes in the present 
study.  In  addition,  no  quantification  or  semi-quantification  of  the  degree  of  MAC  was 
attempted; as a consequence, no evaluation of the degree of MAC could be done in relation 
to incident stroke. 
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In conclusion, the results of the present thesis suggest that:
S1) In hypertension, managed in a real-life context,  clustered metabolic risk factors 
emerged as the most important predictors of inadequate response to therapy and more 
efforts should be devoted to control this condition. Thus, independently of adequacy 
and profusion of pharmacological treatment, clustering of metabolic risk factors like in 
the MetS confers  higher  risk for  uncontrolled BP,  especially  if  diuretics  and RAS-
blockers are not adequately prescribed. 
S2) In  adolescents  and young adults,  without  overt  CV disease,  DM and also pre-
diabetes evaluated by IFG, are strongly associated with preclinical disease which can 
be detected by ultrasound, including increased LV mass, concentric geometry and early 
signs  of  systolic  and  diastolic  dysfunction,  independently  of  major  confounders, 
including body fat and BP. 
S3) In  high  risk  hypertensive  patients  with  electrocardiographic  signs  of  LVH, 
presence of  MAC predicted increased rate  of  ischemic stroke independent  of  other 
well-known clinic, metabolic and echocardiographic confounders of ischemic stroke. 
MAC is often considered a trivial finding, and is even not always reported in routine 
echocardiograms.  Our  analysis  strongly  suggests  that  this  is  not  the  case  and  that 
evidence of MAC should always be highlighted,  especially  in hypertensive patients 
with a high CV risk phenotype.        
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Taken  together,  the  results  of  these  studies  both  have  potential  important  clinical 
impacts  and  also  advance  current  understanding  of  the  pathophysiology  beyond  the 
progression from CV risk factors to clinical disease and may pave the way to new interesting 
future  research  projects.  Further  studies  are  needed  to  elucidate  pathophysiological 
mechanisms beyond the interaction that we have found between metabolic risk factors and 
efficacy of therapy and preclinical and clinical CV disease. Further research is needed to 
confirm and extend the results that we have found, and additional trials should be performed 
specifically on hypertensive patients with MetS, which are confirmed to be the most resistant 
to  standard  anti-hypertensive  therapy.  Further  studies  should  evaluate  whether  the  LV 
structural and functional alterations we have found  related to DM are present also in other 
populations, evaluating also to what extent these findings contribute to the early risk of CV 
disease.  Finally,  whether  in  hypertension  diagnosis  of  MAC  may  improve  stroke  risk 
prediction also beyond detection of carotid plaques and whether hypertensive patients with 
MAC may benefit particularly from more aggressive risk factor modifications and/or platelet 
inhibition  pharmacological  drugs  should  be  tested  in  future  studies.  Future  studies  are 
warranted to evaluate the impact of lifestyles and medical interventions on reduction of the 
metabolic risk factors related to obesity and hypertension and the subsequent improvement in 
BP control and development of pre-clinical and clinical CV disease in general population.
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